Hemangiosarcoma Program Details
Hemangiosarcoma (HSA) is an aggressive cancer in dogs and carries a poor prognosis. There are limited therapeutic options for the treatment of HSA, with none currently providing a significant opportunity for long-term survival. Inclusive of the common ER presentation, surgery, diagnostics/staging, and chemotherapy, HSA impacts numerous specialty services throughout a hospital and accordingly the unmet needs are recognized by all parts of the profession.
Through Discovery’s previous work in hemangiosarcoma (CHAMP; Canine Hemangiosarcoma Molecular Profiling study) we now have new knowledge in HSA that allows truly innovative trials investigating its diagnosis, prognosis, and treatment. The collective data obtained from these planned studies will provide significant translational benefit for humans affected with a similar cancer, angiosarcoma.